Literature DB >> 21212212

A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.

Roshan Ramanathan1, Kawsar R Talaat, Daniel P Fedorko, Siddhartha Mahanty, Theodore E Nash.   

Abstract

We used a species-specific approach to treat 10 patients with cutaneous leishmaniasis diagnosed using polymerase chain reaction. Non-antimony treatments (oral miltefosine, ketoconazole, and liposomal amphotericin B) were chosen as an alternative to pentavalent antimony drugs based on likely or proven drug efficacy against the infecting species. Leishmania Viannia panamensis was diagnosed in three patients and treated successfully with oral ketoconazole. Miltefosine treatment cured two patients with L. infantum chagasi. A wide variety of Leishmania responded to liposomal amphotericin B administered for 5-7 days. Three patients with L. V. braziliensis, one patient with L. tropica, and two patients with L. infantum chagasi were treated successfully. One person with L. V. braziliensis healed slowly because of a resistant bacterial superinfection, and a second patient with L. infantum chagasi relapsed and was retreated with miltefosine. These drugs were reasonably well-tolerated. In this limited case series, alternative non-antimony-based regimens were convenient, safe, and effective.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212212      PMCID: PMC3005496          DOI: 10.4269/ajtmh.2011.10-0437

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  75 in total

1.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Leishmania tropica in northern Israel: a clinical overview of an emerging focus.

Authors:  Ayelet Shani-Adir; Stephanie Kamil; Dganit Rozenman; Eli Schwartz; Michal Ramon; Lucia Zalman; Abed Nasereddin; Charles L Jaffe; Moshe Ephros
Journal:  J Am Acad Dermatol       Date:  2005-09-15       Impact factor: 11.527

Review 3.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

4.  Comparison of PCR assays for diagnosis of cutaneous leishmaniasis.

Authors:  Esther Bensoussan; Abedelmajeed Nasereddin; Flory Jonas; Lionel F Schnur; Charles L Jaffe
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 5.  Overview of liposomes.

Authors:  G Gregoriadis
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

6.  Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.

Authors:  Jorge Arevalo; Luis Ramirez; Vanessa Adaui; Mirko Zimic; Gianfranco Tulliano; César Miranda-Verástegui; Marcela Lazo; Raúl Loayza-Muro; Simonne De Doncker; Anne Maurer; Francois Chappuis; Jean-Claude Dujardin; Alejandro Llanos-Cuentas
Journal:  J Infect Dis       Date:  2007-05-03       Impact factor: 5.226

7.  [Cutaneous leishmaniasis in northern Algeria].

Authors:  S Belazzoug; A Ammar-Khodja; M Belkaid; O Tabet-Derraz
Journal:  Bull Soc Pathol Exot Filiales       Date:  1985

8.  Cutaneous leishmaniasis: treatment with ketoconazole.

Authors:  L Weinrauch; R Livshin; J El-On
Journal:  Cutis       Date:  1983-09

9.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.

Authors:  T R Navin; B A Arana; F E Arana; J D Berman; J F Chajón
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

10.  Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.

Authors:  Herbert Sindermann; Kirsten R Engel; Christina Fischer; Wolfgang Bommer
Journal:  Clin Infect Dis       Date:  2004-10-18       Impact factor: 9.079

View more
  6 in total

Review 1.  Leishmaniasis in the United States: treatment in 2012.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers.

Authors:  Daniel P Eiras; Laura A Kirkman; Henry W Murray
Journal:  Curr Treat Options Infect Dis       Date:  2015-03-01

Review 3.  The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection.

Authors:  Carlos Gustavo Vieira de Morais; Ana Karina Castro Lima; Rodrigo Terra; Rosiane Freire dos Santos; Silvia Amaral Gonçalves Da-Silva; Patrícia Maria Lourenço Dutra
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

4.  A cluster of four cases of cutaneous leishmaniasis by Leishmania donovani in Cyprus: a case series.

Authors:  Maria G Koliou; Yiannakis Antoniou; Maria Antoniou; Vasiliki Christodoulou; Apostolos Mazeris; Elpidoforos S Soteriades
Journal:  J Med Case Rep       Date:  2014-10-24

5.  Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.

Authors:  S Lamotte; N Aulner; G F Späth; E Prina
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

6.  Real-time PCR using FRET technology for Old World cutaneous leishmaniasis species differentiation.

Authors:  Milli Nath-Chowdhury; Mugundhine Sangaralingam; Patrick Bastien; Christophe Ravel; Francine Pratlong; Juan Mendez; Michael Libman; Momar Ndao
Journal:  Parasit Vectors       Date:  2016-05-03       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.